SCHEMBL14729111

SCHEMBL14729111

CS(=O)(=O)c1ccc(-c2ccc3nc(OC4CCN(c5ccc(C(F)(F)F)cn5)CC4)sc3c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.55
DGAT1 O75907 5/20 0.48
KCNH2 Q12809 4/20 0.44
SLC6A9 P48067 1/20 0.44
SLC6A5 Q9Y345 1/20 0.44
HRH3 Q9Y5N1 2/20 0.43
ADORA2A P29274 2/20 0.42
GAA P10253 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
SOAT1 P35610 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ABL1 P00519 1/20 0.41
LMNA P02545 1/20 0.41
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
PTK2 Q05397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14729202 0.94 GPR119 (0.48) GPR119DGAT1KCNH2SLC6A9SLC6A5
SCHEMBL14729200 0.88 GPR119 (0.52) GPR119DGAT1HRH3
SCHEMBL14729105 0.87 GPR119 (0.53) GPR119DGAT1KCNH2ADORA2A
SCHEMBL14729106 0.81 GPR119 (0.51) GPR119
SCHEMBL14729110 0.81 GPR119 (0.49) GPR119ALDH1A1LMNA
SCHEMBL2591328 0.79 GPR119 (0.58) GPR119
SCHEMBL14729112 0.79 GPR119 (0.56) GPR119
SCHEMBL14728896 0.79 GPR119 (0.62) GPR119DGAT1KCNH2HRH3ADORA2A
SCHEMBL14729103 0.79 PIK3CD (0.41) GPR119HRH3ALDH1A1LMNA
SCHEMBL14729109 0.79 ALDH1A1 (0.50) GPR119ALDH1A1KMT2AKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
EP-2566860-B1 BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2014-09-10 EP disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS GPR119, GPR139, GPR4 GPR119 1/4885DGAT1 707/4885KCNH2 1122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.